Recent Headlines
Within Drug Delivery Systems
Nanomi Joins Consortium to Address Chronic Kidney Disease
Nanomi, a leading provider of microsphere-based drug delivery technologies to the pharmaceutical industry, announced today that it joined a consortium for the development of a therapy to prevent chronic kidney disease. In an aging population, the worldwide incidence of chronic kidney disease,... - June 25, 2009 - Nanomi
Genscript Offers Free Bio-Reagent Sample Bundles
GenScript offers high quality bundled bio-reagent samples to appreciate customers and assist in biology research under current tough economic condition. - May 10, 2009 - GenScript USA Inc.
GenScript Seeks Long-Term Collaboration Opportunities by Offering Special Partnership Promotion for Gene Synthesis
Internationally recognized biology contract research organization GenScript Corporation announces its special partnership promotion for gene synthesis service, which aims to establish a long-term, high-volume, and preferred vendor contract with its partners by offering them specially discounted... - April 22, 2009 - GenScript USA Inc.
Carmel Pharma/PhaSeal Exhibiting at Booth #251 at ONS Congress
Offerings Include Interactive Product Efficacy Demos, Opportunities to Speak with PhaSeal Developers, Complimentary Starbucks Cards and More. - April 17, 2009 - Carmel Pharma
April 2009 Declared National Safe Handling Awareness Month
National Campaign Aims to Protect Healthcare Workers from Hazardous Drug Exposure. - February 26, 2009 - Carmel Pharma
Free CE Webinar Offered for First-Ever National Safe Handling Awareness Day (April 20, 2009)
Healthcare professionals are invited to participate in a free, one-hour safe handling CE webinar addressing the proper handling of hazardous drugs on April 20, 2009, the inaugural Safe Handling Awareness Day. - February 24, 2009 - Carmel Pharma
Carmel Pharma/PhaSeal Exhibiting at Booth #1127 at ASHP MCM
Offerings Include Live Leakproof Integrity Test w/ Industry Thought Leaders, New Product Demos, Nintendo Wii Raffle and More. - December 05, 2008 - Carmel Pharma
Physicians Total Care Helps North Carolina Practice Integrate Physician Dispensing
Due to decreased reimbursements from managed care companies, Hickory Family Practice in Hickory, N.C., began looking for different avenues to increase profitability. Integrating physician medication dispensing through Physicians Total Care allowed Hickory Family Practice to generate additional revenue for the practice. - May 27, 2008 - Physicians Total Care
Carmel Pharma Introduces the Next Evolution of PhaSeal
Carmel Pharma, Inc. will introduce the new Injector N35 with ErgoMotion™ at the 33rd ONS Annual Congress in Philadelphia, PA. This new component employs the innovative and unique technology of ErgoMotion™ - a simple turn-key motion that provides easy access during hazardous drug... - May 16, 2008 - Carmel Pharma
Avanti Therapeutics Launches Chikujee Therapeutics, a Targeted Drug Delivery Company
Avanti Therapeutics, a privately held biopharmaceutical company, said it has incubated and launched a new bionanotechnology company for targeted drug delivery called Chikujee Therapeutics. Chikujee Therapeutics hopes to commercialize nanomedicines using its proprietary, cell specific targeted drug... - March 28, 2008 - Chikujee Therapeutics
Samaritan Pharma Strategically Advances Its Promising Alzheimer's Drug
Enters Service Agreement with Advinus Therapeutics, India to Validate Potential Memory Restoring Benefits of Alzheimer's Drug Caprospinol. Strategy is to Bolster Caprospinol Alzheimer's Data Package to Out-License to Big Pharma and Expand IND Application to Enter Human Trials. Samaritan... - January 09, 2008 - Samaritan Pharmaceuticals
Samaritan Announces the Granting of European Patent for New Type of Cardiovascular Plaque Clearing Drug SP-1000
Samaritan Pharmaceuticals has received a notice that a European Patent has been granted to Samaritan's SP-1000 (Cholesterol Recognition Sequence) drug for the treatment of cardiovascular disease. - January 09, 2008 - Samaritan Pharmaceuticals
Three Rivers Adds Territory of Ireland to Samaritan's Existing Exclusive Licensing Agreement to Market Amphocil in Greece and Cyprus
Samaritan has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 09, 2008 - Samaritan Pharmaceuticals
Samaritan Pharmaceuticals Welcomes Two New Independent Directors to Its Board
Samaritan has appointed two new independent members, Jack L. Ayala and Robert W. Crane, to its Board of Directors. Mr. Ayala and Mr. Crane bring valuable experience and their appointment strengthens Samaritan's commitment to maintain a majority of independent members that reflects today's best practices on its Board. Samaritan's board is now comprised of eight independent directors and two internal directors. - January 09, 2008 - Samaritan Pharmaceuticals
FDA Accepts Samaritan's Cushing's SP-6300 IND and Clears Phase II Study
The U.S. Food and Drug Administration (FDA) has completed its regulatory review of Samaritan's IND (Investigational New Drug) application for Cushing's syndrome SP-6300 and declared it has not identified any deficiencies in its IND filing. Accordingly, Samaritan can proceed with its proposed Phase II clinical study of Cushing's syndrome SP-6300's efficacy in patients experiencing Hypercortisolism. - January 04, 2008 - Samaritan Pharmaceuticals
Samaritan Expands Revenue Opportunities with Marketing Authorization Approval for HIV Drug Amphocil in Cyprus
Samaritan Pharmaceuticals, Inc. is pleased to announce that its subsidiary Samaritan Pharmaceuticals Europe, S.A. has received notification, from the Cyprus Ministry of Health, that its marketing authorization for HIV fungus drug Amphocil has been approved in Cyprus. The Cyprus Ministry of Health... - January 03, 2008 - Samaritan Pharmaceuticals
Actors Studio's Anna Strasberg Joins Samaritan Advisory Board of Directors
Ms. Anna Strasberg has joined Samaritan's Advisory Board. Anna Strasberg is best known for continuing the Actors Studio, where the work of her husband Lee Strasberg nurtured the talents of celebrities like Marlon Brando, Robert De Niro, Harvey Keitel, Paul Newman and Al Pacino. - January 03, 2008 - Samaritan Pharmaceuticals
Three Rivers Adds Territory of Ireland to Samaritan's Existing Exclusive Licensing Agreement to Market Amphocil in Greece and Cyprus
Samaritan Pharmaceuticals has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 03, 2008 - Samaritan Pharmaceuticals
EUSA Pharma Signs Exclusive Distribution Agreement with Samaritan for Anesthetic Pain Patch to Launch and Sell in Greece and Cyprus
Samaritan Pharmaceuticals, Inc. has signed an exclusive distribution agreement with EUSA Pharma to launch, promote, sell and support pain patch Rapydan in Greece and Cyprus. - January 03, 2008 - Samaritan Pharmaceuticals
Survey Verifies Link Between Nurses' Illness and Occupational Exposure
Scientists recently released the results of the first ever national survey which assessed nurses’ extent and frequency of exposures to common health care hazards. - December 19, 2007 - Carmel Pharma
Cardiovascular Sciences, Inc. Announces Funding Event
Cardiovascular Sciences, Inc. (CVSC), a corporation under the laws of Nevada, is excited to reveal an initial funding event with Seven Palm Investments, LLC of Illinois. After a recent assessment and restructuring of the company’s equity, the company and its investors are ready to move ahead... - December 12, 2007 - Cardiovascular Sciences, Inc.
Carmel Pharma Introduces the Next Evolution of PhaSeal
Today, Carmel Pharma, Inc. introduces the Injector Luer Lock N35 with ErgoMotion™ during the 42nd ASHP Midyear Clinical Meeting and Exhibition in Las Vegas, NV. - December 03, 2007 - Carmel Pharma
Samaritan Presented Favorable Caprospinol Data at Alzheimer's Drug Development Summit
In an in vivo 'Proof of Concept' study, Samaritan Pharmaceuticals, Inc. has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in vitro data and suggests Caprospinol may not only slow the progress of Alzheimer's, but may also reverse plaque-related brain injuries associated with AD. - November 27, 2007 - Samaritan Pharmaceuticals
Live Continuing Education for Pharmacists on the Safe Handling of Hazardous Drugs
Carmel Pharma, manufacturer and distributor of PhaSeal, announced that they are sponsoring a live, accredited continuing education (CE) seminar during this year’s 42nd Annual ASHP Midyear Clinical Meeting and Exhibition in Las Vegas, NV in December. - November 09, 2007 - Carmel Pharma
World-Renowned Physician and HIV Researcher Joins Samaritan's Advisory Board
Samaritan announced today the appointment of James E.K. Hildreth, M.D., a world renowned physician and HIV researcher, to its Scientific Advisory Board. The work of Dr. Hildreth in HIV/AIDS dates back to 1986 and focuses on blocking HIV infection by learning how HIV gets into cells. He has published more than 80 scientific articles and holds six patents. - October 03, 2007 - Samaritan Pharmaceuticals
Samaritan Licenses Tumor Inhibiting Cancer Drugs That Also Distinguish Cancerous Tumors to Improve on Chemotherapy
Samaritan announced that it has entered into an exclusive licensing agreement with Georgetown University for a patent covering the Peripheral Benzodiazepine Receptor (PBR) which has led to Cancer drug candidates with the ability to inhibit cancerous tumors; and an imaging technique that could possibly distinguish cancerous tumors for a more targeted and improved chemotherapy. - August 21, 2007 - Samaritan Pharmaceuticals
Samaritan Licenses Method to Identify Novel Anti-Tumor Drugs to Increase Cancer Compounds in Pipeline
Samaritan Pharmaceuticals has exclusively licensed a patent application entitled "Structure Based Drug Design of Steroid Inhibitors" from Georgetown University. - August 16, 2007 - Samaritan Pharmaceuticals
Aerotrim Wins £3.9M Order from UK MoD
Aerotrim (Warminster) Ltd has secured a £3.9M order for manufacturing insulation lining for MoD tentage used in field operations. - August 04, 2007 - Aerotrim Group
New Research Presented by MD Anderson and University of Utah Verifies Dry Connections with PhaSeal
New evidence-based research was presented at ONS Congress by MD Anderson and the University of Utah which concluded only the PhaSeal System confined the drug, thus proving the prevention of drug exposure from preparation through administration of hazardous drugs. - May 05, 2007 - Carmel Pharma
Carmel Pharma, Inc. Launches New PhaSeal Preparation Component
Carmel Pharma, Inc. launches their new Protector 28 (P28). This preparation component is the latest advancement of the PhaSeal System and is available now. - May 03, 2007 - Carmel Pharma
Carmel Pharma Offers New Continuing Education Program
Carmel Pharma, manufacturers and distributors of PhaSeal, announced today that they are now offering an accredited continuing education (CE) program developed by STAT Educational Services, an accredited provider of continuing education for various healthcare professionals. - April 25, 2007 - Carmel Pharma
New Evidence-based Research will be Unveiled During 'Ask the Experts’ at ONS Congress in April
New evidence-based research for determining adherence to the NIOSH definition of a closed-system will be unveiled during ‘Ask the Experts’ at the ONS Congress on Wednesday, April 25 in Las Vegas, NV. ‘Ask the Experts’ will be held from 1pm-2pm on Wednesday, April 25 in the... - April 04, 2007 - Carmel Pharma
Blue Sky Biotech, Inc Appoints Scott Gridley, Ph.D., as Senior Research Scientist
Blue Sky Biotech, Inc. announced the June 1st appointment of Scott Gridley, Ph.D., as Senior Research Scientist. Dr. Gridley previously worked for five years in the metabolic diseases division of Sandoz Research Institute (now Novartis Institutes for BioMedical Research) where he was involved in... - August 15, 2006 - Blue Sky Biotech, Inc.
Blue Sky Biotech, Inc Names Dr. Norman Garceau, Former Scientist at Pfizer Global Research and Development, as Chief Scientific Officer
Blue Sky Biotech, Inc. announced the Feb 1st appointment of Norman Garceau, Ph.D., as Chief Scientific Officer. Dr. Garceau previously worked in early drug discovery at the Pfizer Research Technology Center (Cambridge, MA) from 1999 to 2006, engaged in a range of activities that included gene cloning and expression profiling, cell biology, assay development, and lead discovery. - March 15, 2006 - Blue Sky Biotech, Inc.
Hovione Expands its Range of Services in Particle Design Technology
Hovione has increased its range of services and multi-scale facilities in cGMP Spray Drying, an advanced particle design technology. Building on its accumulated expertise in all major areas of API development and cGMP manufacture, a full range of cGMP Spray Drying facilities operating at lab, pilot and industrial scale have now been installed at Hovione's API manufacturing plant in Europe and are currently being installed at Hovione’s Technology Transfer Centre in New Jersey, USA. - August 26, 2005 - Hovione